4th Quarter - Report

THE NICKLES GROUP, LLC for EMERGENT BIOSOLUTIONS

Firm
Client
Income
$37,500
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.

LobbyistCovered position, as disclosed
DONALD KENT —

Contacted: SENATE

Defense DEF

NDAA - provisions related to biological and chemical defense.

LobbyistCovered position, as disclosed
DONALD KENT —

Contacted: SENATE

Health Issues HCR

Re-authorization of the Pandemic and All-Hazards Preparedness Act. Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guideline.

LobbyistCovered position, as disclosed
STACEY HUGHES New U.S. Senate Budget Cmte, Dpty Staff Dir;Ofce of the Asst. Maj. Ldr (Sen. Nickles), Policy Adv; Office of the Asst. Min. Ldr (Sen. Nickles), Policy Adv.;Senate Spec. Cmte on Aging (Sen.Cohen),Prof. Staff Member; U.S.Sen Connie Mack, Leg Asst/Schdlr
DONALD KENT —

Contacted: SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.